New combo therapy for prostate cancer recurrence shows early promise
NCT ID NCT05230251
First seen Nov 01, 2025 · Last updated May 17, 2026 · Updated 32 times
Summary
This early-phase study tested a new approach for men whose prostate cancer returned after initial radiation therapy. It combined standard brachytherapy (internal radiation) with a targeted radioactive drug called 177Lu-PSMA, which seeks out and destroys cancer cells throughout the body. The goal was to see if this combination was safe and feasible. Only 3 men participated, and the study focused on safety and ability to complete treatment, not on curing the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
London Health Sciences Centre
London, Ontario, N6A5W9, Canada
Conditions
Explore the condition pages connected to this study.